Pegilodecakin alone or in combination for heavily pre-treated advanced kidney cancer patients

This study looked at the use of pegilodecakin alone or in combination with immunotherapy or targeted therapy for the treatment of people with advanced solid tumours. Pegilodecakin is a form of cytokine called interleukin-10. The interleukin-10 is attached to a substance called polyethylene glycol (PEG) to improve how the drug works to unleash the immune […]

read more

UK regulator confirms benefits of AstraZeneca vaccine far outweigh the risks

Following suspensions by some countries of the COVID-19 Oxford AstraZeneca COVID-19 vaccine over suspected blood clots, the Medicines and Healthcare Regulatory Authority (MHRA) in the UK confirms that the benefits of the vaccine in preventing COVID-19 far outweigh the risks. People should still go and get their COVID-19 vaccine when asked to do so. Read […]

read more

NHS patients could be offered intravenous cancer treatments at home

In an attempt to reduce treatment backlogs and hospital visits, thousands of NHS patients could be given intravenous cancer treatments in the comfort of their own living rooms. Specialist nurses from The Christie Hospital in Manchester began offering breast cancer patients the option to have their chemotherapy treatments at home in 2016, after a successful […]

read more

Nivolumab/cabozantinib combination approved in EU for first-line kidney cancer treatment

The European Commission has approved the use of the nivolumab plus cabozantinib combination for the first-line treatment of people with advanced renal cell carcinoma (RCC). The combination is now licensed for use within the European Union. The Medicines and Healthcare products Regulatory Agency (MHRA) will need to approve the nivolumab plus cabozantinib combination before it […]

read more

Cancer Research UK Cancer Patient Experience Survey

Cancer Research UK conducted a survey with cancer patients from across the UK to understand the impact of COVID-19 on their testing, treatment, and care, as well as their day-to-day lives and wellbeing. Nearly 2,000 people completed the survey in May 2020 to explore the impact of the COVID-19 pandemic on cancer patients. From this […]

read more

One Cancer Voice: Plotting a route out of the pandemic – an update

We at Kidney Cancer Support Network are part of the One Cancer Voice campaign to find a route of the pandemic for cancer patients and the ensure the UK’s cancer services eventually become world-leading. The campaign last Tuesday 16 March was published in various prestigious news outlets, both online and in press, and consisted of […]

read more

FDA grants priority review for HIF-2α inhibitor belzutifan (MK-6482)

The US Food and Drug Administration (FDA) has granted priority review for a marketing license for the hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, belzutifan. Belzutifan is a new medicine for the treatment of patients with von Hippel-Lindau (VHL) renal cell carcinoma (RCC) who do not need surgery immediately. Kidney cancers frequently have mutations in a gene called the […]

read more

One Cancer Voice: Plotting a route out of the pandemic and towards world-leading cancer services

Governments across the UK have bold ambitions to improve cancer survival and transform patients’ quality of life for the 1 in 2 of us who will be diagnosed with the disease. Decades of hard work have resulted in cancer survival doubling over the last half a century – now half of people diagnosed with cancer […]

read more

Updated results from a trial with belzutifan for people with advanced kidney cancer

Kidney cancers frequently have mutations in the von Hippel-Lindau (VHL) gene, resulting in high levels of a protein called hypoxia-inducible factor, or HIF-2α. This results in a number of changes in the cancer cells and their surrounding environment that favour tumour growth. The novel hypoxia-inducible factor 2α (HIF-2α) inhibitor, belzutifan (MK-6482), blocks the action of HIF-2α. In a small […]

read more

Immune checkpoint inhibitors for sarcomatoid kidney cancer

Sarcomatoid renal cell carcinoma (sRCC) is a rare and aggressive form of RCC in which the tumour cells look like the cells of a sarcoma (cancer of connective tissue such as muscles, nerves, fat, blood vessels etc.). Patients with metastatic RCC with sarcomatoid features are difficult to treat and do not respond well to targeted […]

read more
Showing 1 to 10 of 998 results
  TOP